30 closest matches · ranked by relevance
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
Infectious Skin Disease · Bacterial Skin Disease
Primary: Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) Population — 75; 59; 9; 19 participants
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Bacterial Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population — 84.7; 88.9 percentage of participants
Abscess · Wound Infection · Diabetic Foot
Primary: Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population — 88.6; 89.6 percentage of…
Skin Structure Infections · Bacterial Skin Diseases · Staphylococcal Skin Infections
Primary: Clinical Response at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 33; 37; 31 Participants
Staphylococcal Skin Infection
Primary: Clinical Response — 358; 364; 59; 57 patients
Staphylococcal Skin Infection
Primary: Clinical Response — 323; 321; 52; 58 participants
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 304; 297; 29; 21 participants
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 291; 289; 25; 28 participants
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Skin Diseases, Infectious
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36.1; 36.8; 23.3; 18.4 percentage of participants
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants
Skin Diseases, Infectious · Skin Diseases, Bacterial
Primary: Clinical Response Rate at Test of Cure in the Clinically Evaluable Analysis Set — 98.2; 94.4; 94.4 Percentage of participants
Skin Diseases · Infectious
Primary: Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) — 0.00; 0.01 percentage
Skin Diseases, Bacterial
Primary: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit — 162; 152 participants
Bacterial Infections
Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Methicillin-Resistant Staphylococcus Aureus · Bacterial Infections · Staphylococcal Skin Infections
Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants
Skin and Subcutaneous Tissue Bacterial Infections
Primary: The Early Clinical Response Rate — 283; 276 participants
Staphylococcal Skin Infections
Primary: Infection-Related Hospital Length of Stay — 91.46; 93.23 Hours
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants